RxDoctor Payments Data

Robert Overholt, MD

Allergy & Immunology · Knoxville, TNNPI 1699760736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $603 and has fallen 96.0% since, to $24 in 2024. That places this record below the midpoint for allergy & immunology clinicians in TN, where the typical reported total is $6,300.

$2,266in general payments, 2019–2025

Across 100 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$529
  • AstraZeneca$516
  • Genentech USA, Inc.$393
  • CSL Behring$208
  • Sanofi$105
  • Kaleo, Inc.$92
  • plus $424 from 9 others

What the payments were for

  • Food & beverage$2,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,266 in reported general payments places this provider in the 25th percentile of 79 allergy & immunology providers in Tennessee.

See all allergy & immunology providers in Tennessee

Medicare billing

Part B allowed, 2024
$153,501
Medicare patients
233
Services billed
9,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab41$114,546
Breo ElliptaFluticasone/Vilanterol19$9,789
Advair HfaFluticasone Propion/Salmeterol14$5,095
Arnuity ElliptaFluticasone Furoate17$4,352
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,795
Azelastine Hcl57$2,113
Fluticasone Propionate58$1,152
Albuterol Sulfate HfaAlbuterol Sulfate30$992
Montelukast Sodium54$696
Ipratropium Bromide18$665
Famotidine21$232
Levocetirizine Dihydrochloride13$214
Hydroxyzine Hcl11$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta$529$14,14136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 79 allergy & immunology providers in Tennessee.

Other allergy & immunology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →